HK Stock Market Move | REMEGEN(09995) rose more than 8%, TaiTashiPu gMG China Phase III clinical study selected for 2025 AANEM oral presentation.

REMEGEN (09995) rose more than 8%, as of the time of publication, it increased by 8.29% to 115 Hong Kong dollars, with a turnover of 2.22 billion Hong Kong dollars. On the news front, on September 18th, REMEGEN announced that the innovative drug RC18, a fusion protein of the global first BLyS/APRIL dual target independently developed by the company, was used to treat generalized myasthenia gravis (gMG) Phase III clinical trial data in China, which is to verify the 48-week open label extension study (OLE) data for long-term efficacy. It was selected for oral presentation at the 2025 Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), which will be held at the Hilton San Francisco Union Square on October 29th to November 1st local time. In addition, REMEGEN recently stated at an earnings briefing that in August 2021, the company reached a global exclusive licensing agreement with Seattle Genetics (now acquired by Pfizer Inc.) for the global development and commercialization rights of Vedolizumab (code: RC48) in regions outside REMEGEN (i.e. except for Japan and Singapore) in Asia. Currently, clinical trials of RC48 overseas are being carried out by Pfizer as planned.